This is based on a predicted phosphorylation of the nuclear receptor NR4A2 gene, a family member of AR (NR3C4), and regulation of JUNB and DUSP5, all predicted genes to act as novel upstream regulators of NFκB (see above), suggesting that MAP3K8 would be another important upstream regulator of NFκB in prostate cancer. The gene discussed is NFKB1; the disease is prostate carcinoma.